



Marksans Pharma Ltd.

November 10, 2025

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001
Scrip Code: 524404

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block - G
Bandra-Kurla Complex
Bandra (East), Mumbai - 400051
Symbol: MARKSANS

Sub.: US FDA inspection at Company's 2nd manufacturing facility located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India

Dear Sirs,

This is to inform you that a current Good Manufacturing Practice (cGMP) inspection was conducted by the US FDA at the 2nd manufacturing facility of the Company located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India from 3rd November 2025 to 7th November 2025.

The said inspection concluded with Zero Form 483 observation.

Mr. Mark Saldanha, Managing Director said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”

Please take the above information on record.

Thanking you.

Yours faithfully
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000
E-mail: companysecretary@marksanspharma.com
www.marksanspharma.com